Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | GAA | P10253 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | SOD1 | P00441 | 3/20 | 0.36 |
| ▸ | CYB5R3 | P00387 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
| ▸ | DHODH | Q02127 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12297426 | 0.79 | KMT2A (0.76) | KMT2AMEN1KDM4EALDH1A1GAA | |
| SCHEMBL12297404 | 0.78 | KMT2A (1.00) | KMT2AMEN1KDM4EALDH1A1GAA | |
| SCHEMBL12297457 | 0.75 | KMT2A (0.57) | KMT2AMEN1KDM4EALDH1A1GAA | |
| SCHEMBL19918060 | 0.74 | KMT2A (0.75) | KMT2AMEN1KDM4EALDH1A1GAA | |
| SCHEMBL12297444 | 0.74 | SOD1 (0.36) | KMT2AMEN1KDM4EALDH1A1GAA | |
| SCHEMBL12297448 | 0.70 | SOD1 (0.67) | KMT2AMEN1KDM4EALDH1A1GAA | |
| SCHEMBL13355196 | 0.70 | KDM4E (0.35) | KMT2AMEN1KDM4EALDH1A1GAA | |
| SCHEMBL13355235 | 0.68 | KDM4E (0.49) | KMT2AMEN1KDM4EALDH1A1GAA | |
| SCHEMBL5975794 | 0.66 | KDM4E (0.47) | KMT2AMEN1KDM4EALDH1A1GAA | |
| SCHEMBL7623207 | 0.65 | KDM4E (0.46) | KMT2AMEN1KDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10167263-B2 | Treatment of amyotrophic lateral sclerosis | NORTHWESTERN UNIVERSITY (US) | 2019-01-01 | — | — | US | disclosed |
| EP-2367798-B1 | PYRAZOLONE DERIVATIVES USEFUL IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | UNIV NORTHWESTERN (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20170349552-A1 | Treatment of Amyotrophic Lateral Sclerosis | NORTHWESTERN UNIVERSITY (US) | 2017-12-07 | — | — | US | disclosed |
| US-20170349552-A1 | Treatment of Amyotrophic Lateral Sclerosis | NORTHWESTERN UNIVERSITY (US) | 2017-12-07 | — | — | US | disclosed |
| US-9809556-B2 | Treatment of amyotrophic lateral sclerosis | NORTHWESTERN UNIVERSITY (US) | 2017-11-07 | — | — | US | disclosed |
| US-9809556-B2 | Treatment of amyotrophic lateral sclerosis | NORTHWESTERN UNIVERSITY (US) | 2017-11-07 | — | — | US | disclosed |
| US-20160016911-A1 | Treatment of Amyotrophic Lateral Sclerosis | NORTHWESTERN UNIVERSITY | 2016-01-21 | — | — | US | disclosed |
| US-20160016911-A1 | Treatment of Amyotrophic Lateral Sclerosis | NORTHWESTERN UNIVERSITY | 2016-01-21 | — | — | US | disclosed |
| US-9145424-B2 | Treatment of amyotrophic lateral sclerosis | NORTHWESTERN UNIVERSITY (US) | 2015-09-29 | — | — | US | disclosed |
| US-9145424-B2 | Treatment of amyotrophic lateral sclerosis | NORTHWESTERN UNIVERSITY (US) | 2015-09-29 | — | — | US | disclosed |
| US-20110237907-A1 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CAMBRIA PHARMACEUTICALS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110237907-A1 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CAMBRIA PHARMACEUTICALS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| WO-2010059241-A2 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CAMBRIA PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016911-A1 | Treatment of Amyotrophic Lateral Sclerosis | SMN1; SMN2, SOD1, NLN | KMT2A 3162/4885MEN1 4639/4885KDM4E 2655/4885 |
| US-10167263-B2 | Treatment of amyotrophic lateral sclerosis | SMN1; SMN2, SOD1, NLN | KMT2A 3162/4885MEN1 4639/4885KDM4E 2655/4885 |
| US-20170349552-A1 | Treatment of Amyotrophic Lateral Sclerosis | SMN1; SMN2, SOD1, NLN | KMT2A 3162/4885MEN1 4639/4885KDM4E 2655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.